Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
- Conditions
- Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 61
- Registration Number
- NCT02299765
- Locations
- 🇨🇳
China West Hospital, Chengdu, Sichuan, China
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions
- Drug: AZD9291 80 mg/40 mg + placeboDrug: Placebo AZD9291 80 mg/ 40 mg
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 674
- Registration Number
- NCT02296125
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Blood Detection of EGFR Mutation For Iressa Treatment
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 188
- Registration Number
- NCT02282267
- Locations
- 🇨🇳
beijing Cancer Hospital, Beijing, China
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Conditions
- Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT02179671
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 12
- Registration Number
- NCT02151721
- Locations
- 🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
🇯🇵Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
Combination of Chemotherapy and Gefitinib as First-line Treatment
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Baohui Han
- Target Recruit Count
- 121
- Registration Number
- NCT02148380
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 56
- Registration Number
- NCT02088112
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 27
- Registration Number
- NCT02040064
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
- Conditions
- Non-small Cell Lung Carcinoma
- Interventions
- Biological: PembrolizumabBiological: IpilimumabBiological: Bevacizumab
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 267
- Registration Number
- NCT02039674
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 250
- Registration Number
- NCT02031601
- Locations
- 🇨🇳
Yu Li, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.